Company
BioMérieux SA
Headquarters: Marcy l'Etoile, France
Employees: 13,000
CEO: Mr. Alexandre Merieux
Market Cap
€11.58 Billion
EUR as of Jan. 1, 2025
US$12.05 Billion
BioMérieux SA Categories
France Healthcare Diagnostics & ResearchFrance Healthcare France Diagnostics & Research
Top Competitors by Market Capitalization
Industry: Diagnostics & Research
| Company | Market Cap (USD) |
|---|---|
| Thermo Fisher Scientific | $219.88 B |
| Danaher | $177.43 B |
| Siemens Healthineers AG | $59.19 B |
| Agilent Technologies, Inc. | $43.57 B |
| Lonza Group Ltd | $41.66 B |
Sector:
| Company | Market Cap (USD) |
|---|---|
| Lilly | $689.42 B |
| Novo Nordisk | $622.07 B |
| UnitedHealth Group | $487.54 B |
| Johnson & Johnson | $353.05 B |
| AbbVie | $301.60 B |
Detailed Description
bioMérieux S.A. develops and produces in vitro diagnostic solutions for private and hospital laboratories for the diagnosis of infectious diseases. The company offers systems, which use biological samples to diagnose infectious diseases, cardiovascular pathologies, and various cancers; and microbiological testing of manufacturing primarily for food, pharmaceutical, cosmetics, and veterinary sectors. The company was formerly known as B-D Mérieux. bioMérieux S.A. was founded in 1963 and is headquartered in Marcy l'Etoile, France. bioMérieux S.A. is a subsidiary of Institut Mérieux SA.
Top 1-year algo backtest: +327.04%
$10,000 in March 2024 would now be $42,704 by following this algorithm daily at market close.
Use AI to boost your investing & swing trading, now!
Try Disfold DeepFinance FREE
Financials
| Last Financial Reports Date | June 30, 2018 |
| Revenue TTM | €3.81 B |
| EBITDA | €830.4 M |
| Gross Profit TTM | €2.06 B |
| Profit Margin | 10.81% |
| Operating Margin | 15.16% |
| Quarterly Revenue Growth | 7.40% |
Stocks & Indices
BioMérieux SA has the following listings and related stock indices.
Stock: Euronext: BIM wb_incandescent
Stock: FSX: EYWN wb_incandescent